Statement re. HSE Prosecution
Lab 21 Healthcare, a non-trading Novacyt subsidiary, charged with health and safety offences relating to biological agents at a former facility.
Select text to share a quote on X · sign in to keep highlights & notes in your NCYT notes
Paris, France, and Eastleigh and Manchester, UK - 21 January 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that, following an investigation by the Health and Safety Executive ("HSE"), Lab 21 Healthcare Ltd ("Lab 21"), a non-trading subsidiary of Novacyt, has been charged with health and safety offences relating to a facility it previously operated.
The charges relate to Lab 21's site based at Axminster, Devon and relate to the use of biological agents at the site. The lease for the site was taken over by Lab 21 from Omega Diagnostics Ltd ("Omega"), as part of the acquisition by Lab 21 of Omega's Infectious Diseases business announced on 28 June 2018. The operations that are subject to the charges no longer form any part of the Company's ongoing business.
An initial Magistrates' Court hearing has been set for 18 March 2025.
The Company will make a further announcement following the outcome of the case.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.